Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
The trade increased direct holdings by 17.24%, bringing Roivant Sciences Ltd.'s direct position to 113,317,007 shares post-transaction. All shares were acquired through direct ownership; no indirect entities or derivative instruments were involved. The purchase represents Roivant Sciences Ltd.'s second sizable direct buy in the past year and expands its capacity, with direct ownership now representing 64.65% of Immunovant's outstanding shares. These 10 stocks could mint the next wave of millionaires › Immunovant (NASDAQ:IMVT) spun out of Roivant Sciences Ltd., which reported an open-market purchase of 16,666,666 shares in the biotech company on Dec. 12, 2025, for a total value of ~$350.0 million according to the SEC Form 4 filing Metric Value Shares traded Transaction value $350.0 million Post-transaction shares (direct) Post-transaction value (direct ownership) $3.0 billion Transaction value based on SEC Form 4 reported price ($21.00); post-transaction valu
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- ROIV's page on the SEC website